Indivior raised its sales guidance by over 12% for 2021 as both old and new products keep surpassing expectations of sales. As a result, the adjusted pre-tax income for the current year is expected to be way above the original guidance of the group. The company is not relying on Sublocade, an extended-release injection of Indivior PLC for its revenue this year.
From the point of view of an investor, it is important to assess all rewards and risks before deciding to purchase a share. Carnival Corporation was performing pretty well before the pandemic, but the same cannot be said about this year. As mentioned earlier, the company is just back to business. Cruises have been ordered to function with fewer passengers on board and follow strict sanitization and hygiene protocols. So, tour operator companies are not in great shape right now. Moreover, no technical indicator is pointing towards buying for CCL. All Moving Averages and the majority of oscillators are pointing towards a sell option with a few oscillators being neutral. So, it may not be a good time to invest in CCL shares.
As the company stated, a big order from a criminal justice system customer can increase the sales of Sublocade to £152.91M-£167.48 compared to the previous estimate of £134.71M. Another product of the company is Suboxone film. It has also been declining slower than forecasted, while movements may add a further £7.28M to turnover.
Over twelve months, Indivior PLC’s shares fell 3.7%. The company posted a net loss of £ 107.77M in 2020 on sales of £471.84M. The adjusted net income was £42.96M. The shares rose 10% at the end of June which was the highest in almost two and a half years.